Group A Streptococcus (Strep A) causes a wide range of diseases from relatively mild infections including pharyngitis to more severe illnesses such as invasive diseases and rheumatic heart disease. Authors of the study estimated the cost-effectiveness of a hypothetical Strep A vaccine on multiple disease manifestations at the global-level. Analysis was carried out by building on the potential epidemiological impact of vaccines that align with the WHO’s Preferred Product Characteristics for Strep A vaccines. While the threshold costs for Strep A vaccination being cost-effective are sensitive to vaccine characteristics such as efficacy and waning immunity, a cost-effective Strep A vaccine will lower morbidity and mortality burden in all income settings.
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.